Validation of Bmi1 as a Therapeutic Target of Hepatocellular Carcinoma in Mice
AbstractBmi1 is a member of the polycomb group family of proteins, and it drives the carcinogenesis of various cancers and governs the self-renewal of multiple types of stem cells. Our previous studies have revealed that Bmi1 acts as an oncogene in hepatic carcinogenesis in an INK4a/ARF locus independent manner. However, whether Bmi1 can be used as a potential target for hepatocellular carcinoma treatment has not been fully confirmed yet. Here, we show that perturbation of Bmi1 expression by using short hairpin RNA can inhibit the tumorigenicity and tumor growth of hepatocellular carcinoma cells both in vitro and in vivo. Importantly, Bmi1 knockdown can block the tumor growth, both in the initiating stages and the fast growing stages. Cellular biology analysis revealed that Bmi1 knockdown induces cell cycle arrest and apoptosis. Our findings verify Bmi1 as a qualified treatment target for hepatocellular carcinoma (HCC) and support Bmi1 targeting treatment with chemotherapeutic agents. View Full-Text
Share & Cite This Article
Qi, S.; Li, B.; Yang, T.; Liu, Y.; Cao, S.; He, X.; Zhang, P.; Li, L.; Xu, C. Validation of Bmi1 as a Therapeutic Target of Hepatocellular Carcinoma in Mice. Int. J. Mol. Sci. 2014, 15, 20004-20021.
Qi S, Li B, Yang T, Liu Y, Cao S, He X, Zhang P, Li L, Xu C. Validation of Bmi1 as a Therapeutic Target of Hepatocellular Carcinoma in Mice. International Journal of Molecular Sciences. 2014; 15(11):20004-20021.Chicago/Turabian Style
Qi, Shibo; Li, Bin; Yang, Tan; Liu, Yong; Cao, Shanshan; He, Xingxing; Zhang, Peng; Li, Lei; Xu, Chuanrui. 2014. "Validation of Bmi1 as a Therapeutic Target of Hepatocellular Carcinoma in Mice." Int. J. Mol. Sci. 15, no. 11: 20004-20021.